Tertulia de mayo 2019: “Progresos recientes en el conocimiento y tratamiento del envejecimiento” PONENTE: Dr D MANUEL SERRANO

Publicado el 7 mayo 2019 | Archivado en Actividades Socios, Comunicacion 2.0, Ryder Club de España, Socios, Tertulias Fulbright | Salir del comentario

TERTULIA MARTES 7 de mayo de 2019

20:00 hrs,  Instituto Internacional Americano, Paraninfo

Calle Miguel Angel 8, 28010 Madrid

“Progresos recientes en el conocimiento y tratamiento del envejecimiento”

PONENTE: Dr D MANUEL SERRANO

Manuel Serrano obtained his PhD in 1991, at the University of Madrid (UAM).  From 1991 to 1996, Serrano worked as a postdoctoral researcher in the team of David Beach in Cold Spring Harbor Laboratory, NY.  During this period, Serrano made his most important discovery with the identification and characterization of the gene p16, one of the most important genes for anti-cancer protection and a key inducer of cellular senescence.  Serrano returned to Spain in 1997 to lead a research group, first at the National Center of Biotechnology (CNB), and then, from 2003 to 2017, at the Spanish National Cancer Research Center (CNIO), both in Madrid.  In 2017, Serrano moved to the Institute for Research in Biomedicine (IRB), in Barcelona.

Manuel Serrano is internationally recognized in the field of tumor suppression, senescence and aging. The Serrano team was pioneer in the generation of genetically-modifed mice resistant to damage and cancer.  During the last years, the research interests of his group have extended to cellular reprogramming in relation to aging.  The Serrano laboratory was first in demonstrating that cellular reprogramming into pluripotency is possible within tissues in vivo, and this was considered Advance of the Year 2013 by Nature Medicine.

Now, the focus of his laboratory is to apply their knowledge on senescence and reprogramming to degenerative diseases such as lung, kidney and heart fibrosis, as well as, to cancer therapy.
Manuel Serrano is co-founder and advisor of the start-up company Senolytic Therapeutics based in Boston and Barcelona.

Comentarios

No hay mas respuestas